Free tool
FAERS Monitor: Prevacid
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020406 or its brand name (Prevacid, Lansoprazole). Reports on generic versions are filed under their own applications.
Reports
175,821
Serious
154,728
88% of reports
Hospitalization
65,144
Death reported
20,021
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- chronic kidney disease31,643
- acute kidney injury18,207
- renal failure13,292
- end stage renal disease9,515
- nausea9,315
- renal injury9,275
- diarrhoea9,170
- dyspnoea8,378
- fatigue8,066
- vomiting7,379
- headache7,073
- pain6,868
- off label use6,780
- drug ineffective6,612
- dizziness6,291
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3,206 |
| 2005 | 3,613 |
| 2006 | 3,399 |
| 2007 | 2,906 |
| 2008 | 3,193 |
| 2009 | 3,648 |
| 2010 | 4,397 |
| 2011 | 4,959 |
| 2012 | 5,927 |
| 2013 | 4,692 |
| 2014 | 5,062 |
| 2015 | 7,376 |
| 2016 | 8,061 |
| 2017 | 7,252 |
| 2018 | 24,720 |
| 2019 | 24,506 |
| 2020 | 11,115 |
| 2021 | 9,310 |
| 2022 | 7,978 |
| 2023 | 8,206 |
| 2024 | 8,705 |
| 2025 | 7,937 |
| 2026 | 5,647 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,878,338 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| end stage renal diseaseSignal | 9,515 | 129.2 | 125.6 | 580,226 |
| chronic kidney diseaseSignal | 31,643 | 84.6 | 83.5 | 1,532,023 |
| renal injurySignal | 9,275 | 53.8 | 52.5 | 331,250 |
| acute kidney injurySignal | 18,207 | 16.0 | 15.8 | 227,525 |
| renal failureSignal | 13,292 | 13.2 | 13.0 | 135,654 |
| vomiting | 7,379 | 1.9 | 1.8 | 3,120 |
| dyspnoea | 8,378 | 1.8 | 1.7 | 2,910 |
| diarrhoea | 9,170 | 1.7 | 1.7 | 2,745 |
| dizziness | 6,291 | 1.5 | 1.5 | 1,115 |
| nausea | 9,315 | 1.4 | 1.4 | 1,153 |
| headache | 7,073 | 1.4 | 1.3 | 665 |
| pain | 6,868 | 1.3 | 1.3 | 607 |
| fatigue | 8,066 | 1.2 | 1.2 | 390 |
| off label use | 6,780 | 0.9 | 0.9 | 42 |
| drug ineffective | 6,612 | 0.6 | 0.6 | 1,894 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.